28 February 2019

André van der Ven and Mihai Netea, theme Infectious diseases and global health, and colleagues, will receive 15 million Euro from pharmaceutical company ViiV Healthcare for research into new ways to fight the HIV virus. The aim of the HIV 2000+ project is to identify new drug targets for HIV.

Collaboration will process anonymised patient data, genetic information and environmental factors in order to understand the biology associated with HIV better and identify targets for new medicines earlier. 

ViiV Healthcare is announcing a five-year collaboration with researchers of the Radboudumc, providing dedicated funding to enhance the HIV-specific capability of the Human Functional Genomics Project (HFGP). The HFGP is a large-scale project that combines detailed patient data with cross-omics information, host immune responses and environmental factors to better understand how the body recognizes and defends itself from disease as well as the signs, symptoms and progression of disease.

Under the supervision of a Scientific Management Board (SMB) comprising representatives from Radboudumc and ViiV Healthcare, Radboudumc will expand the cohort of HIV-infected individuals that are part of the HFGP from 200 to 2000 people. Data from this cohort will be used to look at the predictors and pathways of diseases that are specific to people living with HIV and how they might differ from other disease areas and from healthy people who do not have HIV. Using that information, the goal is to identify early stage drug targets that ViiV Healthcare could use to develop new medicines or approaches to treat HIV infection.

The project, called 'HIV 2000+' will be the first comprehensive cohort study in HIV to use a field of biology called 'cross-omics,' which uses genomics, microbiome metagenomics and metabolomics technologies to better understand the underlying biology associated with HIV infection.

Jan van Lunzen, MD PhD, Head of Translational Medical Research at ViiV Healthcare and project coordinator said: “This project will enable us to establish one of the best characterized cohorts of people living with HIV in the world and will not only help to better define biomarkers and pathways of disease progression, but may also serve as a fantastic platform to find new drug targets.”
 
The collaboration will combine Radboudumc’s experience in infectious diseases, established networks and scientific techniques with ViiV Healthcare’s expertise and innovation in discovering and developing medicines for HIV.

Mihai Netea said: “This is a unique, first-time collaboration which will combine in-depth clinical and pathophysiological phenotyping with a systems biology approach in a large population of patients with HIV. It is a unique chance to understand the HIV infection and its complications better, and to partner with ViiV Healthcare to translate that knowledge to the bed of the patient.”

Deal terms

ViiV Healthcare will fully fund the five-year collaboration that will analyze cross-omics data from 2,000 HIV-infected patients and compare this data to that from other disease-areas and to data from healthy volunteers.  Scientists from both Radboudumc and ViiV Healthcare will collaborate closely on the work packages that will be formed as part of the collaboration.

A SMB, comprising members from both Radboudumc and ViiV Healthcare, will provide both scientific and financial oversight of the collaboration. An Independent Scientific Advisory Board will be formed to advise the SMB.

Related news items


Four Veni grants for young RIMLS researchers

22 July 2019

Four young researchers, affiliated to the RIMLS, have each received a Veni grant of 250,000 Euro from NWO. Our researchers received this prestigious grant for their remarkable and original talent and their ability to carry out innovative research.

read more

Bas Loomans received Mid-Career Award

18 July 2019

Bas Loomans received in Vancouver the STEPHEN BAYNE MID-CAREER AWARD of the International Association for Dental Research (IADR)

read more

4,8 million euros for prevention of tuberculosis among people with diabetes in Africa

16 July 2019

Reinout van Crevel and Lindsey te Brake have received European funding of 4.8 million euros to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.

read more

50.000 grant for Paul de Jonge and Harry Dolstra

15 July 2019

Paul de Jonge and Harry Dolstra, theme Cancer development and immune defense, received a €50.000,- (NWA-IDG) grant for their project regarding cancer immunotherapy.

read more

Handbook of biomarkers and precision medicine a new publication by Alain van Gool

12 July 2019

Alain van Gool published a new handbook on biomarkers and applications in (pre)clinical drug development for precision medicine.

read more

The real impact of menstrual complaints on work and school productivity

8 July 2019

Menstrual period symptoms may be linked to nearly nine days of lost productivity every year, through presenteeism, suggests the largest study of its kind, published in the journal BMJ Open. But the real impact on women and society is underestimated and poorly appreciated, say the researchers.

read more